Should we measure C-reactive protein on earth or just on JUPITER?
- PMID: 20394038
- PMCID: PMC6653384
- DOI: 10.1002/clc.20681
Should we measure C-reactive protein on earth or just on JUPITER?
Abstract
Evidence for the role of inflammation in the pathogenesis of atherosclerosis is compelling and has generated interest in high-sensitivity C-reactive protein (hs-CRP) as a marker of cardiovascular risk. Data regarding hs-CRP and cardiovascular risk, though largely consistent, is of unclear clinical relevance. Most recently, the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial has led to further debate regarding the utility of hs-CRP. This article provides a comprehensive review of the data regarding cardiovascular risk and hs-CRP with an emphasis on the JUPITER trial and concludes with an evidence-based analysis of the current role of hs-CRP in cardiovascular risk assessment.
Copyright 2010 Wiley Periodicals, Inc.
References
-
- Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. N Engl J Med 2008; 359(21): 2195–2207. - PubMed
-
- Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation 2001; 104(15): 1863–1867. - PubMed
-
- Kushner I. C‐reactive protein and the acute‐phase response. Hosp Pract (Off Ed) 1990; 25(3A): 13,16,21–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
